DexCom, Inc. (NASDAQ:DXCM) – Equities research analysts at Northcoast Research dropped their Q2 2017 earnings per share estimates for shares of DexCom in a research note issued on Wednesday. Northcoast Research analyst E. Snyder now forecasts that the medical device company will post earnings of ($0.21) per share for the quarter, down from their previous forecast of ($0.18). Northcoast Research also issued estimates for DexCom’s Q3 2017 earnings at ($0.10) EPS, Q4 2017 earnings at $0.05 EPS and FY2017 earnings at ($0.74) EPS.
A number of other research firms have also commented on DXCM. B. Riley restated a “buy” rating and set a $95.00 price target on shares of DexCom in a research report on Tuesday, May 2nd. William Blair restated an “outperform” rating on shares of DexCom in a research report on Thursday, April 27th. Jefferies Group LLC decreased their price target on DexCom to $91.00 and set a “buy” rating on the stock in a research report on Tuesday, May 9th. Piper Jaffray Companies restated a “buy” rating and set a $78.00 price target on shares of DexCom in a research report on Wednesday, July 12th. Finally, Canaccord Genuity decreased their price target on DexCom from $95.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 3rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $89.47.
ILLEGAL ACTIVITY WARNING: “Q2 2017 EPS Estimates for DexCom, Inc. (DXCM) Reduced by Analyst” was first reported by BBNS and is owned by of BBNS. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://baseballnewssource.com/markets/q2-2017-eps-estimates-for-dexcom-inc-dxcm-reduced-by-analyst-updated/1308158.html.
DexCom (DXCM) opened at 67.05 on Friday. DexCom has a 12 month low of $57.68 and a 12 month high of $96.38. The firm’s market cap is $5.79 billion. The firm’s 50-day moving average price is $72.63 and its 200-day moving average price is $75.71.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Tuesday, May 2nd. The medical device company reported ($0.49) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.06. DexCom had a negative return on equity of 32.94% and a negative net margin of 14.70%. The company had revenue of $142.30 million during the quarter, compared to analyst estimates of $143.94 million.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its position in DexCom by 4.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 110,292 shares of the medical device company’s stock valued at $6,586,000 after buying an additional 4,682 shares in the last quarter. Norges Bank bought a new position in DexCom during the fourth quarter valued at about $27,815,000. Teachers Advisors LLC raised its position in DexCom by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 184,560 shares of the medical device company’s stock valued at $11,018,000 after buying an additional 7,050 shares in the last quarter. Highbridge Capital Management LLC bought a new position in DexCom during the fourth quarter valued at about $2,983,000. Finally, Chevy Chase Trust Holdings Inc. bought a new position in DexCom during the first quarter valued at about $3,600,000.
In other news, CEO Kevin R. Sayer sold 8,649 shares of the firm’s stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $68.39, for a total value of $591,505.11. Following the transaction, the chief executive officer now directly owns 347,329 shares in the company, valued at approximately $23,753,830.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Steven Robert Pacelli sold 1,450 shares of the firm’s stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $78.19, for a total value of $113,375.50. The disclosure for this sale can be found here. Insiders sold a total of 36,331 shares of company stock worth $2,548,619 over the last quarter. Corporate insiders own 1.70% of the company’s stock.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with our FREE daily email newsletter.